Trevi Therapeutics, Inc.
Heffernan Michael Thomas sold 39,473 shares of Trevi Therapeutics, Inc. (TRVI) at an average of $15.09 ($15.09–$15.88, $0.60M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
Trevi Therapeutics (TRVI) reported phase III trials for chronic cough treatment, targeting unmet needs. The company's nalbuphine drug has a unique mechanism and strong IP, with funding secured until early 2030, according to a Morgan Stanley conference presentation.
Simply Wall St reports Trevi Therapeutics (TRVI) has started Phase 3 and Phase 2B chronic cough trials and says it has about $188M in cash, cash equivalents and marketable securities at year-end 2025, supporting a runway into 2028. The article cites TRVI shares at $18.50 and a fair value narrative of $26.18.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TRVI (Trevi Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TRVI coverage spans technology, financial news and insider activity.
In the last 30 days, TRVI insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($596K). The most active reporter was Heffernan Michael Thomas with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may exert slight downward pressure on TRVI stock.
Advancement to Phase III suggests higher probability of product approval, which could boost stock valuation.
Trial kickoff and stated funding runway support a bullish re-rating narrative, but the article flags ongoing losses and possible dilution risk.
The filing updates the Haduvio clinical timeline and extends cash runway into 2030, which can re-rate probability-weighted trial outcomes and near-term financing risk.
Initiation can move the stock if investors treat it as a proxy for upcoming catalysts, but the article provides no such catalyst details.
AlphAI scores every news story that mentions TRVI with an AI model for sentiment and relevance, and aggregates insider trades from Trevi Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Heffernan Michael Thomas sold 39,473 shares of Trevi Therapeutics, Inc. (TRVI) at an average of $15.09 ($15.09–$15.88, $0.60M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readTrevi Therapeutics (TRVI) reported phase III trials for chronic cough treatment, targeting unmet needs. The company's nalbuphine drug has a unique mechanism and strong IP, with funding secured until early 2030, according to a Morgan Stanley conference presentation.
2 min readSimply Wall St reports Trevi Therapeutics (TRVI) has started Phase 3 and Phase 2B chronic cough trials and says it has about $188M in cash, cash equivalents and marketable securities at year-end 2025, supporting a runway into 2028. The article cites TRVI shares at $18.50 and a fair value narrative of $26.18.
6 min readTrevi Therapeutics, Inc. (TRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in t
7 min readAnalysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
2 min readTrevi Therapeutics (NASDAQ:TRVI) shares rose 9.85% to $19.07 after management highlighted clinical results for Haduvio, an extended-release nalbuphine oral treatment for refractory chronic cough (RCC) and idiopathic pulmonary fibrosis (IPF). The company cited a $14B to $15B chronic cough market by 2035. It plans a Phase 2b trial in 2H 2026.
5 min readGSK plc reported phase III results for camlipixant, a P2X3 receptor antagonist, from the Calm-1 and Calm-2 trials. According to GSK, the Calm-1 trial met its primary endpoint, with 50 mg twice daily reducing 24-hour cough frequency versus placebo at week 12. GSK’s walk-away from the program also highlighted Trevi Therapeutics’ Haduvio, which had positive phase II data in June.
4 min readTrevi Therapeutics shares rose 13.10% to $19.64 after the company presented clinical data on Haduvio (nalbuphine extended-release) for chronic cough at the European Respiratory Society Cough Conference in London. Trevi said results show a statistically significant cough-frequency reduction across IPF-related and refractory chronic cough. Analysts cited a $21.10 average target; Trevi also reported a June $162 million net offering.
6 min readTrevi Therapeutics (NASDAQ: TRVI) has scheduled an End-of-Phase 2 meeting with the FDA in Q1 2026 to discuss its chronic cough program for idiopathic pulmonary fibrosis (IPF) patients, focusing on its investigational therapy Haduvio. The company plans to initiate a Phase 2b trial for refractory chronic cough in H1 2026 and expects to launch its Phase 3 program for nalbuphine ER in the IPF patient population in H1 2026. Despite being pre-revenue, Trevi boasts a strong financial position, with significant stock performance gains and positive analyst outlooks.
2 min readHC Wainwright & Co. has reiterated its 'Buy' rating for Trevi Therapeutics (TRVI), maintaining a price target of $21.00, signaling confidence in the company's future growth. This follows a series of positive analyst ratings from various firms in late 2025, which also raised price targets. Trevi Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing Haduvio for chronic cough indications and prurigo nodularis.
2 min read
